{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:09:56Z","timestamp":1791684596190,"version":"4.3.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U1903210"],"award-info":[{"award-number":["U1903210"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31870879"],"award-info":[{"award-number":["31870879"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971520"],"award-info":[{"award-number":["81971520"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Peking-Tsinghua Center for Life Sciences"},{"name":"Peking University People\u2019s Hospital Research and Development Foundation","award":["RDX2019-03"],"award-info":[{"award-number":["RDX2019-03"]}]},{"name":"Peking University Clinical Scientist Program, supported by the Fundamental Research Funds for the Central Universities","award":["BMU2019LCKXJ004"],"award-info":[{"award-number":["BMU2019LCKXJ004"]}]},{"name":"the Clinical Medicine Plus X-Young scholars Project of Peking University, supported by the Fundamental Research Funds for the Central Universities","award":["PKU2020LCXQ018"],"award-info":[{"award-number":["PKU2020LCXQ018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s40744-021-00301-3","type":"journal-article","created":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T12:02:31Z","timestamp":1618401751000},"page":"835-847","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Treatment of Active Idiopathic Inflammatory Myopathies by Low-Dose Interleukin-2: A Prospective Cohort Pilot Study"],"prefix":"10.1007","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct04062019","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Miao","family":"Miao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuebo","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9709-1532","authenticated-orcid":false,"given":"Xiaolin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3904-8928","authenticated-orcid":false,"given":"Jing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2590-6242","authenticated-orcid":false,"given":"Zhanguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,14]]},"reference":[{"issue":"12","key":"301_CR1","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","volume":"75","author":"K Mariampillai","year":"2018","unstructured":"Mariampillai K, Granger B, Amelin D, Guiguet M, Hachulla E, Maurier F, et al. Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies. JAMA Neurol. 2018;75(12):1528.","journal-title":"JAMA Neurol"},{"key":"301_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nrrheum.2010.2","volume":"6","author":"MC Dalakas","year":"2010","unstructured":"Dalakas MC. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol. 2010;6:129\u201337.","journal-title":"Nat Rev Rheumatol"},{"key":"301_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.autrev.2011.06.007","volume":"11","author":"I Marie","year":"2011","unstructured":"Marie I, Mouthon L. Therapy of polymyositis and dermatomyositis. Autoimmun Rev. 2011;11:6\u201313.","journal-title":"Autoimmun Rev"},{"key":"301_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216246","author":"SX Zhang","year":"2019","unstructured":"Zhang SX, Wang J, Sun HH, Zhang JQ, Liu GY, Luo J, et al. Circulating regulatory T cells were absolutely decreased in dermatomyositis\/polymyositis patients and restored by low-dose IL-2. Ann Rheum Dis. 2019. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216246.","journal-title":"Ann Rheum Dis"},{"key":"301_CR5","doi-asserted-by":"publisher","first-page":"105912","DOI":"10.1016\/j.intimp.2019.105912","volume":"77","author":"M Feng","year":"2019","unstructured":"Feng M, Guo H, Zhang C, Wang Y, Liang Z, Zhao X, et al. Absolute reduction of regulatory T cells and regulatory effect of short-term and low-dose IL-2 in polymyositis or dermatomyositis. Int Immunopharmacol. 2019;77:105912.","journal-title":"Int Immunopharmacol"},{"key":"301_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","volume":"79","author":"J He","year":"2020","unstructured":"He J, Zhang R, Shao M, Zhao X, Miao M, Chen J, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2020;79:141\u20139.","journal-title":"Ann Rheum Dis"},{"key":"301_CR7","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/nm.4148","volume":"22","author":"J He","year":"2016","unstructured":"He J, Zhang X, Wei Y, Sun X, Chen Y, Deng J, et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat Med. 2016;22:991\u20133.","journal-title":"Nat Med"},{"key":"301_CR8","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1016\/S2665-9913(19)30018-9","volume":"1","author":"JY Humrich","year":"2019","unstructured":"Humrich JY, Spee-Mayer C, Siegert E, Bertolo M, Rose A, Abdirama D, et al. Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. Lancet Rheumatol. 2019;1:e44-54.","journal-title":"Lancet Rheumatol"},{"key":"301_CR9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","volume":"78","author":"M Rosenzwajg","year":"2019","unstructured":"Rosenzwajg M, Lorenzon R, Cacoub P, Pham HP, Pitoiset F, El Soufi K, et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis. 2019;78:209\u201317.","journal-title":"Ann Rheum Dis"},{"key":"301_CR10","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s13555-020-00421-8","volume":"105","author":"M Miao","year":"2020","unstructured":"Miao M, Li Y, Huang B, He J, Li Z. Hypomyopathic dermatomyositis with refractory dermatitis treated by low-dose IL-2. Dermatol Ther (Heidelb). 2020;105:1181\u20134.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"301_CR11","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344\u20137.","journal-title":"N Engl J Med"},{"key":"301_CR12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292:403\u20137.","journal-title":"N Engl J Med"},{"key":"301_CR13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1590\/S1806-37132011000100015","volume":"371","author":"J Solomon","year":"2011","unstructured":"Solomon J, Swigris JJ, Brown KK. Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol. 2011;371:100\u20139.","journal-title":"J Bras Pneumol"},{"issue":"5","key":"301_CR14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","volume":"14","author":"JE Hoogendijk","year":"2004","unstructured":"Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, the Netherlands. Neuromuscul Disord. 2004;14(5):337\u201345.","journal-title":"Neuromuscul Disord"},{"issue":"775","key":"301_CR15","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/annrheumdis-2017-212047","volume":"05","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Marder G, Koontz DC, Nandkumar P, Qi Z, Oddis CV. Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis. Ann Rheum Dis. 2018;05(775):720\u20137.","journal-title":"Ann Rheum Dis"},{"key":"301_CR16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1148\/radiol.2373041515","volume":"2381","author":"K Ichikado","year":"2006","unstructured":"Ichikado K, Suga M, Muranaka H, Gushima Y, Miyakawa H, Tsubamoto M, et al. Prediction of prognosis for acute respiratory distress syndrome with thin-section CT: validation in 44 cases. Radiology. 2006;2381:321\u20139.","journal-title":"Radiology"},{"key":"301_CR17","first-page":"603","volume":"30","author":"LG Rider","year":"2003","unstructured":"Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, et al. Defining clinical improvement in adult and juvenile myositis. J Rheumatol. 2003;30:603\u201317.","journal-title":"J Rheumatol"},{"key":"301_CR18","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1002\/art.20349","volume":"50","author":"LG Rider","year":"2004","unstructured":"Rider LG, Giannini EH, Brunner HI, Ruperto N, JamesNewton L, Reed AM, et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum. 2004;50:2281\u201390.","journal-title":"Arthritis Rheum"},{"key":"301_CR19","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","volume":"76","author":"R Aggarwal","year":"2017","unstructured":"Aggarwal R, Rider LG, Ruperto N, Bayat N, Erman B, Feldman BM, et al. 2016 American College of Rheumatology\/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis. 2017;76:792\u2013801.","journal-title":"Ann Rheum Dis"},{"key":"301_CR20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13075-016-0974-5","volume":"18","author":"JM Pandya","year":"2016","unstructured":"Pandya JM, Loell I, Hossain MS, Zong M, Alexanderson H, Raghavan S, et al. Effects of conventional immunosuppressive treatment on CD244+ (CD28null) and FOXP3+ T cells in the inflamed muscle of patients with polymyositis and dermatomyositis. Arthritis Res Ther. 2016;18:80.","journal-title":"Arthritis Res Ther"},{"key":"301_CR21","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","volume":"365","author":"D Saadoun","year":"2011","unstructured":"Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med. 2011;365:2067\u201377.","journal-title":"N Engl J Med"},{"key":"301_CR22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaut.2015.01.001","volume":"58","author":"M Rosenzwajg","year":"2015","unstructured":"Rosenzwajg M, Churlaud G, Mallone R, et al. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. J Autoimmun. 2015;58:48\u201358.","journal-title":"J Autoimmun"},{"key":"301_CR23","doi-asserted-by":"publisher","first-page":"e1002139","DOI":"10.1371\/journal.pmed.1002139","volume":"13","author":"JA Todd","year":"2016","unstructured":"Todd JA, Evangelou M, Cutler AJ, et al. Regulatory T cell responses in participants with type 1 diabetes after a single dose of interleukin-2: a non-randomised, open label, adaptive dose-finding trial. PLoS Med. 2016;13:e1002139.","journal-title":"PLoS Med"},{"key":"301_CR24","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","volume":"365","author":"J Koreth","year":"2011","unstructured":"Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365:2055\u201366.","journal-title":"N Engl J Med"},{"key":"301_CR25","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.2337\/db12-0049","volume":"61","author":"SA Long","year":"2012","unstructured":"Long SA, Rieck M, Sanda S, et al. Rapamycin\/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function. Diabetes. 2012;61:2340\u20138.","journal-title":"Diabetes"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-021-00301-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-021-00301-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-021-00301-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T18:07:44Z","timestamp":1628618864000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-021-00301-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,14]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["301"],"URL":"https:\/\/doi.org\/10.1007\/s40744-021-00301-3","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,14]]},"assertion":[{"value":"14 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}